Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Non-Current Deffered Revenue: 2009-2010

Historic Non-Current Deffered Revenue for Cumberland Pharmaceuticals (CPIX) over the last 2 years, with Dec 2010 value amounting to $558.0 billion.

  • Cumberland Pharmaceuticals' Non-Current Deffered Revenue rose 231.98% to $558.0 billion in Q4 2010 from the same period last year, while for Dec 2010 it was $558.0 billion, marking a year-over-year increase of 231.98%. This contributed to the annual value of $558.0 billion for FY2010, which is 231.98% up from last year.
  • Latest data reveals that Cumberland Pharmaceuticals reported Non-Current Deffered Revenue of $558.0 billion as of FY2010, which was up 231.98% from $168.1 billion recorded in FY2009.
  • In the past 5 years, Cumberland Pharmaceuticals' Non-Current Deffered Revenue ranged from a high of $558.0 billion in FY2010 and a low of $168.1 billion during FY2009.
  • Its 2-year average for Non-Current Deffered Revenue is $363.1 billion, with a median of $363.1 billion in 2009.
  • Data for Cumberland Pharmaceuticals' Non-Current Deffered Revenue shows a peak YoY surged of 231.98% (in 2010) over the last 5 years.
  • Cumberland Pharmaceuticals' Non-Current Deffered Revenue (Yearly) stood at $168.1 billion in 2009, then surged by 231.98% to $558.0 billion in 2010.